Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
Identifieur interne : 001506 ( Istex/Corpus ); précédent : 001505; suivant : 001507Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
Auteurs : Dimitrios J. Tsakiris ; Vianda S. Stel ; Patrik Finne ; Emily Fraser ; James Heaf ; Johan De Meester ; Sabine Schmaldienst ; Friedo Dekker ; Enrico Verrina ; Kitty J. JagerSource :
- Nephrology Dialysis Transplantation [ 0931-0509 ] ; 2010-04.
Abstract
Background. Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry. Methods. Thirteen national registries providing data on patients who started RRT from 19862005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender. Results. Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 19861990 to 2.52 pmp in 20012005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.652.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years. Conclusion. The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.
Url:
DOI: 10.1093/ndt/gfp679
Links to Exploration step
ISTEX:3FC664A8C811E1AF1E2799DD91202B468A345D60Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title><author><name sortKey="Tsakiris, Dimitrios J" sort="Tsakiris, Dimitrios J" uniqKey="Tsakiris D" first="Dimitrios J." last="Tsakiris">Dimitrios J. Tsakiris</name><affiliation><mods:affiliation>Department of Nephrology, General Hospital Papageorgiou of Thessaloniki, Greece</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Stel, Vianda S" sort="Stel, Vianda S" uniqKey="Stel V" first="Vianda S." last="Stel">Vianda S. Stel</name><affiliation><mods:affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Finne, Patrik" sort="Finne, Patrik" uniqKey="Finne P" first="Patrik" last="Finne">Patrik Finne</name><affiliation><mods:affiliation>Finnish Registry for Kidney Diseases, Helsinki, Finland</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Fraser, Emily" sort="Fraser, Emily" uniqKey="Fraser E" first="Emily" last="Fraser">Emily Fraser</name><affiliation><mods:affiliation>Scottish Renal Registry, Glasgow Royal Infirmary, Glasgow G4 0SF, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Heaf, James" sort="Heaf, James" uniqKey="Heaf J" first="James" last="Heaf">James Heaf</name><affiliation><mods:affiliation>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev, Hospital University of Copenhagen, Denmark</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="De Meester, Johan" sort="De Meester, Johan" uniqKey="De Meester J" first="Johan" last="De Meester">Johan De Meester</name><affiliation><mods:affiliation>Dutch-speaking Belgian Renal Registry, Belgium</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Schmaldienst, Sabine" sort="Schmaldienst, Sabine" uniqKey="Schmaldienst S" first="Sabine" last="Schmaldienst">Sabine Schmaldienst</name><affiliation><mods:affiliation>Medical University of Vienna, Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Dekker, Friedo" sort="Dekker, Friedo" uniqKey="Dekker F" first="Friedo" last="Dekker">Friedo Dekker</name><affiliation><mods:affiliation>Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Verrina, Enrico" sort="Verrina, Enrico" uniqKey="Verrina E" first="Enrico" last="Verrina">Enrico Verrina</name><affiliation><mods:affiliation>Nephrology and Dialysis Unit, G. Gaslini Institute, Genoa, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Jager, Kitty J" sort="Jager, Kitty J" uniqKey="Jager K" first="Kitty J." last="Jager">Kitty J. Jager</name><affiliation><mods:affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3FC664A8C811E1AF1E2799DD91202B468A345D60</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1093/ndt/gfp679</idno><idno type="url">https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001506</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title><author><name sortKey="Tsakiris, Dimitrios J" sort="Tsakiris, Dimitrios J" uniqKey="Tsakiris D" first="Dimitrios J." last="Tsakiris">Dimitrios J. Tsakiris</name><affiliation><mods:affiliation>Department of Nephrology, General Hospital Papageorgiou of Thessaloniki, Greece</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Stel, Vianda S" sort="Stel, Vianda S" uniqKey="Stel V" first="Vianda S." last="Stel">Vianda S. Stel</name><affiliation><mods:affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Finne, Patrik" sort="Finne, Patrik" uniqKey="Finne P" first="Patrik" last="Finne">Patrik Finne</name><affiliation><mods:affiliation>Finnish Registry for Kidney Diseases, Helsinki, Finland</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Fraser, Emily" sort="Fraser, Emily" uniqKey="Fraser E" first="Emily" last="Fraser">Emily Fraser</name><affiliation><mods:affiliation>Scottish Renal Registry, Glasgow Royal Infirmary, Glasgow G4 0SF, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Heaf, James" sort="Heaf, James" uniqKey="Heaf J" first="James" last="Heaf">James Heaf</name><affiliation><mods:affiliation>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev, Hospital University of Copenhagen, Denmark</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="De Meester, Johan" sort="De Meester, Johan" uniqKey="De Meester J" first="Johan" last="De Meester">Johan De Meester</name><affiliation><mods:affiliation>Dutch-speaking Belgian Renal Registry, Belgium</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Schmaldienst, Sabine" sort="Schmaldienst, Sabine" uniqKey="Schmaldienst S" first="Sabine" last="Schmaldienst">Sabine Schmaldienst</name><affiliation><mods:affiliation>Medical University of Vienna, Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna, Austria</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Dekker, Friedo" sort="Dekker, Friedo" uniqKey="Dekker F" first="Friedo" last="Dekker">Friedo Dekker</name><affiliation><mods:affiliation>Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Verrina, Enrico" sort="Verrina, Enrico" uniqKey="Verrina E" first="Enrico" last="Verrina">Enrico Verrina</name><affiliation><mods:affiliation>Nephrology and Dialysis Unit, G. Gaslini Institute, Genoa, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author><author><name sortKey="Jager, Kitty J" sort="Jager, Kitty J" uniqKey="Jager K" first="Kitty J." last="Jager">Kitty J. Jager</name><affiliation><mods:affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>Dimitrios Tsakiris;</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Nephrology Dialysis Transplantation</title><title level="j" type="abbrev">Nephrol Dial Transplant</title><idno type="ISSN">0931-0509</idno><idno type="eISSN">1460-2385</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010-04">2010-04</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="1200">1200</biblScope><biblScope unit="page" to="1206">1206</biblScope></imprint><idno type="ISSN">0931-0509</idno></series><idno type="istex">3FC664A8C811E1AF1E2799DD91202B468A345D60</idno><idno type="DOI">10.1093/ndt/gfp679</idno><idno type="ArticleID">gfp679</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0931-0509</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background. Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry. Methods. Thirteen national registries providing data on patients who started RRT from 19862005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender. Results. Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 19861990 to 2.52 pmp in 20012005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.652.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years. Conclusion. The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Dimitrios J. Tsakiris</name><affiliations><json:string>Department of Nephrology, General Hospital Papageorgiou of Thessaloniki, Greece</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Vianda S. Stel</name><affiliations><json:string>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Patrik Finne</name><affiliations><json:string>Finnish Registry for Kidney Diseases, Helsinki, Finland</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Emily Fraser</name><affiliations><json:string>Scottish Renal Registry, Glasgow Royal Infirmary, Glasgow G4 0SF, UK</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>James Heaf</name><affiliations><json:string>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev, Hospital University of Copenhagen, Denmark</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Johan de Meester</name><affiliations><json:string>Dutch-speaking Belgian Renal Registry, Belgium</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Sabine Schmaldienst</name><affiliations><json:string>Medical University of Vienna, Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna, Austria</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Friedo Dekker</name><affiliations><json:string>Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, The Netherlands</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Enrico Verrina</name><affiliations><json:string>Nephrology and Dialysis Unit, G. Gaslini Institute, Genoa, Italy</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item><json:item><name>Kitty J. Jager</name><affiliations><json:string>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</json:string><json:string>Dimitrios Tsakiris;</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>haemodialysis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>incidence</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple myeloma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>light-chain deposit disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>peritoneal dialysis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>survival</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>transplantation</value></json:item></subject><articleId><json:string>gfp679</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Background. Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry. Methods. Thirteen national registries providing data on patients who started RRT from 19862005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender. Results. Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 19861990 to 2.52 pmp in 20012005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.652.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years. Conclusion. The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.</abstract><qualityIndicators><score>8.5</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>1855</abstractCharCount><pdfWordCount>5462</pdfWordCount><pdfCharCount>32526</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>310</abstractWordCount></qualityIndicators><title>Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title><genre><json:string>research-article</json:string></genre><host><volume>25</volume><publisherId><json:string>ndt</json:string></publisherId><pages><last>1206</last><first>1200</first></pages><issn><json:string>0931-0509</json:string></issn><issue>4</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2385</json:string></eissn><title>Nephrology Dialysis Transplantation</title></host><categories><wos><json:string>TRANSPLANTATION</json:string><json:string>UROLOGY & NEPHROLOGY</json:string></wos></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1093/ndt/gfp679</json:string></doi><id>3FC664A8C811E1AF1E2799DD91202B468A345D60</id><score>0.22619614</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></availability><date>2009-12-27</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title><author xml:id="author-1"><persName><forename type="first">Dimitrios J.</forename><surname>Tsakiris</surname></persName><affiliation>Department of Nephrology, General Hospital Papageorgiou of Thessaloniki, Greece</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-2"><persName><forename type="first">Vianda S.</forename><surname>Stel</surname></persName><affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-3"><persName><forename type="first">Patrik</forename><surname>Finne</surname></persName><affiliation>Finnish Registry for Kidney Diseases, Helsinki, Finland</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-4"><persName><forename type="first">Emily</forename><surname>Fraser</surname></persName><affiliation>Scottish Renal Registry, Glasgow Royal Infirmary, Glasgow G4 0SF, UK</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-5"><persName><forename type="first">James</forename><surname>Heaf</surname></persName><affiliation>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev, Hospital University of Copenhagen, Denmark</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-6"><persName><forename type="first">Johan</forename><surname>de Meester</surname></persName><affiliation>Dutch-speaking Belgian Renal Registry, Belgium</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-7"><persName><forename type="first">Sabine</forename><surname>Schmaldienst</surname></persName><affiliation>Medical University of Vienna, Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna, Austria</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-8"><persName><forename type="first">Friedo</forename><surname>Dekker</surname></persName><affiliation>Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-9"><persName><forename type="first">Enrico</forename><surname>Verrina</surname></persName><affiliation>Nephrology and Dialysis Unit, G. Gaslini Institute, Genoa, Italy</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author><author xml:id="author-10"><persName><forename type="first">Kitty J.</forename><surname>Jager</surname></persName><affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation></author></analytic><monogr><title level="j">Nephrology Dialysis Transplantation</title><title level="j" type="abbrev">Nephrol Dial Transplant</title><idno type="pISSN">0931-0509</idno><idno type="eISSN">1460-2385</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2010-04"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="1200">1200</biblScope><biblScope unit="page" to="1206">1206</biblScope></imprint></monogr><idno type="istex">3FC664A8C811E1AF1E2799DD91202B468A345D60</idno><idno type="DOI">10.1093/ndt/gfp679</idno><idno type="ArticleID">gfp679</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-12-27</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Background. Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry. Methods. Thirteen national registries providing data on patients who started RRT from 19862005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender. Results. Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 19861990 to 2.52 pmp in 20012005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.652.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years. Conclusion. The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>haemodialysis</term></item><item><term>incidence</term></item><item><term>multiple myeloma</term></item><item><term>light-chain deposit disease</term></item><item><term>peritoneal dialysis</term></item><item><term>survival</term></item><item><term>transplantation</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-12-27">Created</change><change when="2010-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-id journal-id-type="hwp">ndt</journal-id><journal-title>Nephrology Dialysis Transplantation</journal-title><abbrev-journal-title abbrev-type="pubmed">Nephrol Dial Transplant</abbrev-journal-title><issn pub-type="ppub">0931-0509</issn><issn pub-type="epub">1460-2385</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/ndt/gfp679</article-id><article-id pub-id-type="publisher-id">gfp679</article-id><article-categories><subj-group subj-group-type="heading"><subject>Dialysis</subject></subj-group></article-categories><title-group><article-title>Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</article-title><alt-title alt-title-type="left-running">D.J. Tsakiris <italic>et al.</italic></alt-title><alt-title alt-title-type="right-running">Incidence and outcome of myeloma or LCDD patients on RRT</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tsakiris</surname><given-names>Dimitrios J.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stel</surname><given-names>Vianda S.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Finne</surname><given-names>Patrik</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fraser</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Heaf</surname><given-names>James</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>de Meester</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Schmaldienst</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dekker</surname><given-names>Friedo</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Verrina</surname><given-names>Enrico</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Jager</surname><given-names>Kitty J.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Nephrology</addr-line>, <institution>General Hospital “Papageorgiou” of Thessaloniki</institution>, <country>Greece</country></aff><aff id="af2"><label>2</label><addr-line>ERA-EDTA Registry, Academic Medical Center</addr-line>, <institution>University of Amsterdam</institution>, <addr-line>Department of Medical Informatics, Amsterdam</addr-line>, <country>The Netherlands</country></aff><aff id="af3"><label>3</label><institution>Finnish Registry for Kidney Diseases</institution>, <addr-line>Helsinki</addr-line>, <country>Finland</country></aff><aff id="af4"><label>4</label><addr-line>Scottish Renal Registry</addr-line>, <institution>Glasgow Royal Infirmary</institution>, <addr-line>Glasgow G4 0SF</addr-line>, <country>UK</country></aff><aff id="af5"><label>5</label><addr-line>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev</addr-line>, <institution>Hospital University of Copenhagen</institution>, <country>Denmark</country></aff><aff id="af6"><label>6</label><institution>Dutch-speaking Belgian Renal Registry</institution>, <country>Belgium</country></aff><aff id="af7"><label>7</label><institution>Medical University of Vienna</institution>, <addr-line>Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna</addr-line>, <country>Austria</country></aff><aff id="af8"><label>8</label><institution>Leiden University Medical Centre</institution>, <addr-line>Department of Clinical Epidemiology, Leiden</addr-line>, <country>The Netherlands</country></aff><aff id="af9"><label>9</label><addr-line>Nephrology and Dialysis Unit</addr-line>, <institution>G. Gaslini Institute</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><author-notes><corresp> Dimitrios Tsakiris; E-mail:
<email>dimtsak@otenet.gr</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2009</year></pub-date><volume>25</volume><issue>4</issue><fpage>1200</fpage><lpage>1206</lpage><history><date date-type="received"><day>15</day><month>11</month><year>2008</year></date><date date-type="rev-recd"><day>11</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Oxford University Press</copyright-holder></permissions><abstract><p><bold>Background.</bold> Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry.</p><p><bold>Methods.</bold> Thirteen national registries providing data on patients who started RRT from 1986–2005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender.</p><p><bold>Results.</bold> Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 1986–1990 to 2.52 pmp in 2001–2005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.65–2.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years.</p><p><bold>Conclusion.</bold> The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.</p></abstract><kwd-group><title>Keywords</title><kwd>haemodialysis</kwd><kwd>incidence</kwd><kwd>multiple myeloma</kwd><kwd>light-chain deposit disease</kwd><kwd>peritoneal dialysis</kwd><kwd>survival</kwd><kwd>transplantation</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study</title></titleInfo><name type="personal"><namePart type="given">Dimitrios J.</namePart><namePart type="family">Tsakiris</namePart><affiliation>Department of Nephrology, General Hospital Papageorgiou of Thessaloniki, Greece</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vianda S.</namePart><namePart type="family">Stel</namePart><affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrik</namePart><namePart type="family">Finne</namePart><affiliation>Finnish Registry for Kidney Diseases, Helsinki, Finland</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Emily</namePart><namePart type="family">Fraser</namePart><affiliation>Scottish Renal Registry, Glasgow Royal Infirmary, Glasgow G4 0SF, UK</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James</namePart><namePart type="family">Heaf</namePart><affiliation>Danish Society of Nephrology, National Registry Department of Nephrology B Herlev, Hospital University of Copenhagen, Denmark</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Johan</namePart><namePart type="family">de Meester</namePart><affiliation>Dutch-speaking Belgian Renal Registry, Belgium</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sabine</namePart><namePart type="family">Schmaldienst</namePart><affiliation>Medical University of Vienna, Department of Medicine III, Div. Of Nephrology and Dialysis, Vienna, Austria</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Friedo</namePart><namePart type="family">Dekker</namePart><affiliation>Leiden University Medical Centre, Department of Clinical Epidemiology, Leiden, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Enrico</namePart><namePart type="family">Verrina</namePart><affiliation>Nephrology and Dialysis Unit, G. Gaslini Institute, Genoa, Italy</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kitty J.</namePart><namePart type="family">Jager</namePart><affiliation>ERA-EDTA Registry, Academic Medical Center, University of Amsterdam, Department of Medical Informatics, Amsterdam, The Netherlands</affiliation><affiliation>Dimitrios Tsakiris;</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2010-04</dateIssued><dateCreated encoding="w3cdtf">2009-12-27</dateCreated><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Background. Information on demographics and survival of patients starting renal replacement therapy (RRT) for end-stage renal disease (ESRD) due to multiple myeloma (MM) or light-chain deposit disease (LCDD) is scarce. The aim of this study was to describe the incidence, characteristics, causes of death and survival rates of RRT for ESRD due to MM or LCDD in the ERA-EDTA Registry. Methods. Thirteen national registries providing data on patients who started RRT from 19862005 to the ERA-EDTA Registry participated. Incidence per million population (pmp) of RRT for ESRD due to MM or LCDD and other causes (non-MM) was observed overtime. Patient survival on RRT was examined, unadjusted and adjusted for age and gender. Results. Of the 159 637 patients on RRT, 2453 (1.54%) had MM or LCDD. The incidence of RRT for ESRD due to MM or LCDD, adjusted for age and gender, increased from 0.70 pmp in 19861990 to 2.52 pmp in 20012005. MM and LCDD patients compared to non-MM patients were older and a higher percentage was on haemodialysis at day 91 after the start of RRT. The most common causes of death in MM and LCDD patients were malignancy (36.1%), cardiovascular causes (17.2%) and infection (14.7%). MM and LCDD patients had a 2.77 (95% CI, 2.652.90) higher risk of death compared to non-MM patients. The unadjusted median survival on RRT was 0.91 years in MM and LCDD patients and 4.46 years in non-MM patients. During follow-up, 35 patients were transplanted and their mean survival was 9.6 years. Conclusion. The incidence of RRT for ESRD due to MM or LCDD has increased over the past 20 years in Europe. The median patient survival on RRT for MM and LCDD patients was 0.91 years, compared to 4.46 years for non-MM patients. These results suggest that dialysis, and in selected cases even transplantation, should be offered to MM and LCDD patients.</abstract><subject><genre>Keywords</genre><topic>haemodialysis</topic><topic>incidence</topic><topic>multiple myeloma</topic><topic>light-chain deposit disease</topic><topic>peritoneal dialysis</topic><topic>survival</topic><topic>transplantation</topic></subject><relatedItem type="host"><titleInfo><title>Nephrology Dialysis Transplantation</title></titleInfo><titleInfo type="abbreviated"><title>Nephrol Dial Transplant</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0931-0509</identifier><identifier type="eISSN">1460-2385</identifier><identifier type="PublisherID">ndt</identifier><identifier type="PublisherID-hwp">ndt</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>1200</start><end>1206</end></extent></part></relatedItem><identifier type="istex">3FC664A8C811E1AF1E2799DD91202B468A345D60</identifier><identifier type="DOI">10.1093/ndt/gfp679</identifier><identifier type="ArticleID">gfp679</identifier><accessCondition type="use and reproduction" contentType="copyright">The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource><recordOrigin>Oxford University Press</recordOrigin></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/covers/tiff</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/annexes/gif</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/3FC664A8C811E1AF1E2799DD91202B468A345D60/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">TRANSPLANTATION</classCode><classCode scheme="WOS">UROLOGY & NEPHROLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001506 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001506 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3FC664A8C811E1AF1E2799DD91202B468A345D60
|texte= Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study
}}
| This area was generated with Dilib version V0.6.25. |  |